Spyre Therapeutics, Inc. (SYRE)

85.34 +5.44 (+6.81%) USD  |  NASDAQ  |  Oct 19, 15:33
More

Spyre Therapeutics Cash from Operations (Annual) : -169.41M for Dec. 31, 2025

Cash from Operations (Annual) Chart

Historical Cash from Operations (Annual) Data

View and export this data back to 2014. Start Trial.
Date Value
December 31, 2025 -169.41M
December 31, 2024 -157.82M
December 31, 2023 -99.91M
December 31, 2022 -80.14M
December 31, 2021 -53.72M
December 31, 2020 -75.78M
Date Value
December 31, 2019 -65.69M
December 31, 2018 -32.19M
December 31, 2017 -24.62M
December 31, 2016 -18.84M
December 31, 2015 -10.98M
December 31, 2014 -7.335M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
AbbVie, Inc. 19.03B
Incyte Corp. 1.413B
SELLAS Life Sciences Group, Inc. -28.39M
Relay Therapeutics, Inc. -235.46M
ACADIA Pharmaceuticals, Inc. 109.84M